相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms
Mario Cazzola et al.
BLOOD (2014)
Gene Expression Profiling in True Interval Breast Cancer Reveals Overactivation of the mTOR Signaling Pathway
Federico Rojo et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Cancer Cells Exploit eIF4E2-Directed Synthesis of Hypoxia Response Proteins to Drive Tumor Progression
James Uniacke et al.
CANCER RESEARCH (2014)
Pten regulates homeostasis and inflammation-induced migration of myelocytes in zebrafish
Zhi-Wei Dong et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Ral and Rheb GTPase Activating Proteins Integrate mTOR and GTPase Signaling in Aging, Autophagy, and Tumor Cell Invasion
Timothy D. Martin et al.
MOLECULAR CELL (2014)
Transcriptional Profiling of Whole Blood Identifies a Unique 5-Gene Signature for Myelofibrosis and Imminent Myelofibrosis Transformation
Hans Carl Hasselbalch et al.
PLOS ONE (2014)
Proliferation and Survival Signaling from Both Jak2-V617F and Lyn Involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 Cell Line Newly Established from Acute Myeloid Leukemia Transformed from Polycythemia Vera
Toshikage Nagao et al.
PLOS ONE (2014)
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms
Niccolo Bartalucci et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2013)
Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera
Miguel Gallardo et al.
MOLECULAR CANCER (2013)
Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells
Warren Fiskus et al.
MOLECULAR CANCER THERAPEUTICS (2013)
JAK/STAT signaling in hematological malignancies
W. Vainchenker et al.
ONCOGENE (2013)
mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
Costanza Bogani et al.
PLOS ONE (2013)
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia
Sarah K. Tasian et al.
BLOOD (2012)
Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+progenitors of essential thrombocythaemia and myelofibrosis patients
Luisa Vicari et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer
Adrian Britschgi et al.
CANCER CELL (2012)
Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis
Vibe Skov et al.
EXPERIMENTAL HEMATOLOGY (2012)
JAK-STAT and AKT pathway-coupled genes in erythroid progenitor cells through ontogeny
Vladan P. Cokic et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
Paola Guglielmelli et al.
BLOOD (2011)
Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms
Lizz F. Grimwade et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Mammalian target of rapamycin activity is required for expansion of CD34+ hematopoietic progenitor cells
Christian R. Geest et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth
Jingxiang Huang et al.
BIOCHEMICAL JOURNAL (2008)
Deregulation of the Akt pathway in human cancer
Eriko Tokunaga et al.
CURRENT CANCER DRUG TARGETS (2008)
Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of essential thrombocythemia
Pascal Mossuz et al.
EXPERIMENTAL HEMATOLOGY (2008)
Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia
E. Puigdecanet et al.
LEUKEMIA (2008)
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
L. S. Steelman et al.
LEUKEMIA (2008)
JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling
Sven Schwernmers et al.
EXPERIMENTAL HEMATOLOGY (2007)
Molecular profiling of CD34(+) cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1)
Paola Guglielmelli et al.
STEM CELLS (2007)
Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients
Sue Chow et al.
EXPERIMENTAL HEMATOLOGY (2006)
Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation
H Raslova et al.
BLOOD (2006)
Mammalian target of rapamycin is required for thrombopoietin-induced proliferation of megakaryocyte progenitors
AL Drayer et al.
STEM CELLS (2006)
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
R Kralovics et al.
BLOOD (2005)
Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays
LC Jones et al.
STEM CELLS (2005)
Gene expression profiling in polycythaemia vera:: overexpression of transcription factor NF-E2
PS Goerttler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB
CH Dai et al.
EXPERIMENTAL HEMATOLOGY (2005)
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells
E Tenedini et al.
BLOOD (2004)
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
K Inoki et al.
GENES & DEVELOPMENT (2003)
分享论文
